Study guide

8.3 Non-Sterile Compounding and NAPRA Standards

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

8.3 Non-Sterile Compounding and NAPRA Standards

Key Takeaways Explain This Topic AI

The NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations establish three distinct levels of compounding risk: Level A (simple/routine, designated clean area), Level B (complex or small-quantity hazardous with local exhaust/containment), and Level C (hazardous compounding requiring negative pressure, dedicated C-PEC, and ISO standards).

Master Formulation Records (the recipe detailing ingredients, instructions, and BUD justification) and Compounding Records (the individual batch log detailing lots, weights, and verifier initials) are legally mandatory quality assurance records.

Default Beyond-Use Dates (BUDs) under NAPRA/USP <795> without specific stability data are: 14 days refrigerated (2-8°C) for water-containing oral liquids, 30 days room temperature for water-containing topicals/semi-solids, and 6 months (or earliest component expiry) for non-aqueous formulations.

Crucial compounding techniques include geometric dilution for uniform blending of potent powders, levigation with an insoluble wetting agent to reduce particle size, and pulverization by intervention for crystalline materials using a volatile solvent.

Equipment verification requires knowledge of balance sensitivity and the Minimum Weighable Quantity (MWQ) formula: MWQ = Sensitivity Requirement Maximum Allowable Error % \text{MWQ} = \frac{\text{Sensitivity Requirement}}{\text{Maximum Allowable Error \%}} MWQ = Maximum Allowable Error % Sensitivity Requirement ​ , ensuring weighing errors never exceed 5%.

Last updated: August 2026

8.3 Non-Sterile Compounding and NAPRA Standards

Exam Focus: The National Association of Pharmacy Regulatory Authorities (NAPRA) non-sterile compounding standards mandate rigorous facility requirements, risk-level assessments, documentation systems, Beyond-Use Dating (BUD), and quality assurance procedures that candidates must master for the PEBC Evaluating Examination.

NAPRA Compounding Framework and Risk Categorization

In Canada, pharmacy compounding is governed by provincial adoption of the NAPRA Model Standards for Pharmacy Compounding of Non-Sterile Preparations and Health Canada Policy 0051 (distinguishing compounding from manufacturing). Compounding is defined as the preparation of a customized therapeutic product pursuant to a specific patient-prescriber relationship, whereas manufacturing involves industrial batch production with a Drug Identification Number (DIN). +-------------------------------------------------------------------------+

  • | NAPRA NON-STERILE COMPOUNDING RISK LEVELS |
  • +-------------------------------------------------------------------------+
  • | |
  • | [LEVEL A: SIMPLE / BASELINE COMPOUNDING] |
  • | - Simple formulations, non-hazardous active ingredients |
  • | - Dedicated clean, uncluttered space; smooth non-porous surfaces |
  • | - Away from high-traffic workflows and air currents |
  • | |
  • | [LEVEL B: COMPLEX / INTERMEDIATE COMPOUNDING] |
  • | - Specialized equipment (e.g., capsule machines, homogenizers) |
  • | - Small quantities of hazardous powders generating airborne dust |
  • | - Dedicated enclosed room; local exhaust / Containment Enclosure (CVE) |
  • | |
  • | [LEVEL C: HAZARDOUS NON-STERILE COMPOUNDING] |
  • | - High-risk NIOSH hazardous drugs (e.g., antineoplastics, hormones) |
  • | - Negative pressure room (-0.01 to -0.03 inches of water column) |
  • | - Externally vented C-PEC (Class I BSC or CVE with HEPA filtration) |
  • | - Minimum 12 Air Changes Per Hour (ACPH) |
  • | |
  • +-------------------------------------------------------------------------+

Level Facility & Environmental Requirements Equipment & Ventilation Representative Preparations

Level A Dedicated compounding zone within dispensary; smooth, impermeable, cleanable surfaces. Standard calibrated balances, mortars/pestles, hot plates. No specialized exhaust required. Simple topical creams/ointments (e.g., hydrocortisone in Glaxal base), non-hazardous oral suspensions (e.g., omeprazole in sodium bicarbonate).

Level B Enclosed separate room separated from dispensary; dedicated wash station and surfaces. Containment Ventilated Enclosure (CVE) or powder hood if handling irritating/dusty powders. Multi-ingredient complex troches, bulk capsule formulations, compounding with minor volatile irritants.

Level C Negative pressure room ( − 0.01 to − 0.03 inches w.g. -0.01\text{ to }-0.03\text{ inches w.g.} − 0.01 to − 0.03 inches w.g. ), minimum 12 ACPH 12\text{ ACPH} 12 ACPH , sealed doors. Externally vented Containment Primary Engineering Control (C-PEC; Class I BSC or CVE with HEPA). Hazardous hormone powders (e.g., testosterone, progesterone, estradiol), hazardous cytotoxic powders (e.g., methotrexate, hydroxyurea suspensions).

Mandatory Documentation: MFR versus Compounding Record

NAPRA standards mandate two distinct, interdependent levels of documentation for every compounded preparation:

1. Master Formulation Record (MFR) - "The Recipe"

The MFR is the approved, immutable master blueprint designed before compounding. It details:

Official or assigned name, strength, and dosage form of the preparation.

Complete list of active and inactive ingredients with exact quantities and chemical grades (e.g., USP, NF, BP grade; Certificate of Analysis [CoA] required for bulk powders).

Step-by-step compounding instructions, mixing speeds, temperatures, and equipment required.

Stability literature citations justifying the assigned Beyond-Use Date (BUD) and storage conditions.

Container-closure system specifications (e.g., light-resistant amber glass, airtight pump).

Quality control parameters (e.g., physical appearance, pH range, weight variation tolerance, color, odor).

Patient counseling requirements and auxiliary warnings.

2. Compounding Record (Log) - "The Batch History"

The Compounding Record is the individualized, legal execution log completed for each specific batch. It records:

Reference to the underlying Master Formulation Record (MFR).

Exact manufacturer, lot numbers, and expiration dates of all raw ingredients used.

Actual measured weights and volumes (including signed balance verification tapes).

Internal lot number and assigned BUD specific to that batch.

Initials/signatures of the compounding personnel (technician/student) and the verifying pharmacist.

Total quantity compounded and percentage yield.

Documented quality control check results (e.g., physical appearance, measured pH).

Beyond-Use Dating (BUD) for Non-Sterile Preparations

In the absence of specific, validated stability-indicating studies in peer-reviewed literature, pharmacists must strictly apply conservative default BUD limits established under NAPRA and USP <795>. +-------------------------------------------------------------------------+

  • | DEFAULT NON-STERILE BUD MATRIX |
  • +-------------------------------------------------------------------------+
  • | |
  • | [NON-AQUEOUS FORMULATIONS] |
  • | - Ointments, non-aqueous gels, powders, capsules, suppositories |
  • | - BUD: Earliest API expiration date OR 6 MONTHS (Whichever is shorter) |
  • | - Storage: Controlled Room Temperature (20°C - 25°C) |
  • | |
  • | [WATER-CONTAINING ORAL FORMULATIONS] |
  • | - Aqueous oral suspensions, oral solutions, syrups |
  • | - BUD: Maximum 14 DAYS |
  • | - Storage: Controlled Refrigeration (2°C - 8°C) |
  • | |
  • | [WATER-CONTAINING TOPICAL / DERMAL / MUCOSAL SEMI-SOLIDS] |
  • | - Aqueous creams, lotions, topical gels |
  • | - BUD: Maximum 30 DAYS |
  • | - Storage: Controlled Room Temperature (20°C - 25°C) |
  • | |
  • +-------------------------------------------------------------------------+

Rule of Precedence: If any raw chemical component has an expiration date shorter than the default BUD period, the preparation's BUD must never exceed that component's expiration date.

  • Pharmaceutical Compounding Techniques and Excipients
  • Powder Blending and Particle Size Reduction

Trituration: Continuous rubbing or grinding of a solid substance in a mortar with a pestle to reduce particle size to a fine powder (comminution) or to blend powders.

Porcelain Mortar: Rough interior surface, ideal for comminution of hard crystalline materials.

Glass Mortar: Non-porous, smooth surface, ideal for blending liquids, staining chemicals (e.g., iodine), or suspensions.

Wedgewood Mortar: Porous, durable ceramic, preferred for grinding powders.

Levigation ("Wet Grinding"): Reducing the particle size of a solid by grinding it in a mortar or spatulating it on an ointment slab with a small amount of a viscous liquid ( levigating agent ) in which the solid is insoluble.

Mineral Oil: Preferred levigating agent for oleaginous/hydrophobic bases (e.g., white petrolatum, Aquaphor).

Glycerin / Propylene Glycol: Preferred levigating agents for aqueous/water-washable bases (e.g., Glaxal base, Cetaphil, PEG ointment).

Geometric Dilution: A critical blending technique used when mixing a potent active drug powder of small quantity with a large volume of inert diluent. The potent drug is combined with an equal volume of diluent, thoroughly triturated, and the process is repeated exponentially (doubling volume each step) to ensure homogeneous distribution.

Pulverization by Intervention: Used for gummy or crystalline substances that resist mechanical grinding (e.g., camphor, iodine). A volatile solvent (such as ethanol) is added to dissolve the substance, triturated on an ointment tile, and as the solvent evaporates, the drug recrystallizes as an ultra-fine powder.

Physicochemical Stability and Degradation Pathways

Hydrolysis: Cleavage of chemical bonds by water, common in esters (e.g., aspirin), amides (e.g., lidocaine), and lactams (e.g., penicillins). Prevented by lyophilization, non-aqueous solvents, and buffering.

Oxidation: Electron loss catalyzed by light, oxygen, or trace heavy metals, causing color change (e.g., epinephrine turns pink/brown). Prevented by adding antioxidants (e.g., ascorbic acid, sodium metabisulfite, BHT) and chelating agents (e.g., EDTA).

Balance Sensitivity and Minimum Weighable Quantity (MWQ)

When using a Class A prescription torsion balance or electronic balance, the Minimum Weighable Quantity (MWQ) ensures that the relative weighing error does not exceed the accepted professional tolerance of 5 % 5\% 5% ( 0.05 0.05 0.05 ): MWQ = Sensitivity Requirement (SR) Maximum Allowable Error % = SR 0.05 = SR × 20 \text{MWQ} = \frac{\text{Sensitivity Requirement (SR)}}{\text{Maximum Allowable Error \%}} = \frac{\text{SR}}{0.05} = \text{SR} \times 20 MWQ = Maximum Allowable Error % Sensitivity Requirement (SR) ​ = 0.05 SR ​ = SR × 20

Example: For a Class A torsion balance with a Sensitivity Requirement (SR) of 6 mg 6\text{ mg} 6 mg , the MWQ = 6 mg 0.05 = 120 mg \text{MWQ} = \frac{6\text{ mg}}{0.05} = 120\text{ mg} MWQ = 0.05 6 mg ​ = 120 mg . Weighing any quantity below 120 mg 120\text{ mg} 120 mg directly on this balance creates an unacceptable error exceeding 5 % 5\% 5% , requiring an aliquot dilution.